Syntonix Pharmaceuticals, Inc. and Boehringer Ingelheim have announced that they have entered into a collaboration to optimize certain Boehringer Ingelheim therapeutic peptides for inhalation, using Syntonix' SynFusion™ and Transceptor™ technologies.
Under the terms of the agreement, Syntonix will receive an upfront fee and research support. Boehringer Ingelheim has the option to develop and commercialize the peptide candidates.
Syntonix will receive milestone and royalty payments on any products developed and commercialized under the agreement.
"We believe that Syntonix' Transceptor and SynFusion technologies have the potential to create significant improvements in the pulmonary delivery of peptides to treat serious human diseases," commented Mikael Dolsten, M.D., Ph.D., Head of Corporate Division Pharma Research Boehringer Ingelheim.
"Boehringer Ingelheim is a leader in the field of inhaled pharmaceuticals," commented Alan Bitonti, Ph.D., Vice President, Research and Development of Syntonix.
"We are especially pleased with this collaboration because it represents our second major partnership involving an inhaled drug with a leading pharmaceutical company this year and it is our first in the area of therapeutic peptides."
"Our technologies, Transceptor and SynFusion, enable both efficient transport through the lung epithelium and an increase in the circulating half- life of protein and peptide drugs," continued Dr. Bitonti.
"The ability to replace frequent injections with better tolerated, less-frequent inhalation represents a significant advancement with regard to patient convenience and compliance."